Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
LMAT 
LeMaitre Vascular Inc (LMAT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: LMAT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 30.7% | Avg. Invested days 48 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.95B USD | Price to earnings Ratio 44.88 | 1Y Target Price 105.62 |
Price to earnings Ratio 44.88 | 1Y Target Price 105.62 | ||
Volume (30-day avg) 266884 | Beta 0.88 | 52 Weeks Range 61.89 - 109.31 | Updated Date 04/2/2025 |
52 Weeks Range 61.89 - 109.31 | Updated Date 04/2/2025 | ||
Dividends yield (FY) 0.94% | Basic EPS (TTM) 1.93 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 20.03% | Operating Margin (TTM) 23.07% |
Management Effectiveness
Return on Assets (TTM) 7.27% | Return on Equity (TTM) 13.87% |
Valuation
Trailing PE 44.88 | Forward PE 38.02 | Enterprise Value 1807056015 | Price to Sales(TTM) 8.89 |
Enterprise Value 1807056015 | Price to Sales(TTM) 8.89 | ||
Enterprise Value to Revenue 8.22 | Enterprise Value to EBITDA 27.07 | Shares Outstanding 22558600 | Shares Floating 20574825 |
Shares Outstanding 22558600 | Shares Floating 20574825 | ||
Percent Insiders 8.86 | Percent Institutions 95.6 |
Analyst Ratings
Rating 4.1 | Target Price 98.78 | Buy 3 | Strong Buy 4 |
Buy 3 | Strong Buy 4 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
LeMaitre Vascular Inc
Company Overview
History and Background
LeMaitre Vascular Inc. was founded in 1983 and is headquartered in Burlington, Massachusetts. It began as a small business focused on manufacturing vascular grafts and has since expanded its product portfolio through internal development and acquisitions, establishing itself as a leader in the vascular surgery space.
Core Business Areas
- Cardiovascular: LeMaitre designs, markets, and sells a range of medical devices used in cardiovascular surgeries. This includes grafts, valvulotomes, occlusion balloons, and other specialized instruments.
Leadership and Structure
The leadership team includes George W. LeMaitre (Chairman & CEO). The company operates with a functional organizational structure, with departments focused on product development, sales, marketing, manufacturing, and regulatory affairs.
Top Products and Market Share
Key Offerings
- XenoSure Graft: A biologically derived vascular graft. Competitors include W.L. Gore & Associates, Getinge AB, and Medtronic. No specific market share data available.
- Valvulotomes: Instruments used to disrupt valves within veins in preparation for vein harvesting for bypass surgery. Competitors include Bard and Getinge AB. No specific market share data available.
- Occlusion Balloons: Used in vascular procedures to temporarily block blood flow. Competitors include Cook Medical. No specific market share data available.
Market Dynamics
Industry Overview
The vascular surgery device market is driven by an aging population, increasing prevalence of vascular diseases, and technological advancements in minimally invasive surgical techniques. The market is competitive with larger players and niche specialists.
Positioning
LeMaitre Vascular Inc. occupies a strong position in the market due to its specialized product portfolio and focus on vascular surgery. Its competitive advantages include strong brand recognition within its niche, established distribution channels, and a commitment to innovation.
Total Addressable Market (TAM)
The global vascular surgery devices market is estimated to be valued at $8.95 Billion in 2024 and is expected to reach $13.82 Billion by 2032. LeMaitre Vascular Inc. is positioned to capture a portion of this expanding market through its specialized product offerings and ongoing innovation.
Upturn SWOT Analysis
Strengths
- Specialized product portfolio
- Strong brand recognition in vascular surgery
- Established distribution channels
- Commitment to innovation
Weaknesses
- Smaller size compared to larger competitors
- Reliance on specific surgical procedures
- Limited product diversification outside vascular surgery
Opportunities
- Expansion into emerging markets
- Development of new products through R&D
- Acquisitions of complementary businesses
- Increased adoption of minimally invasive surgical techniques
Threats
- Increased competition from larger medical device companies
- Pricing pressures from healthcare providers
- Regulatory changes in the medical device industry
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- W.L. Gore & Associates (Private)
- Medtronic (MDT)
- Getinge AB (GETI-B.ST)
- Cook Medical (Private)
Competitive Landscape
LeMaitre Vascular Inc. faces competition from larger medical device companies with greater resources. Its advantages include a focused product portfolio, strong brand reputation, and established distribution network. Disadvantages include smaller size and limited product diversification.
Major Acquisitions
Prolucent Medical
- Year: 2023
- Acquisition Price (USD millions): 17
- Strategic Rationale: Expanded LeMaitre's product portfolio in the vascular access space.
Growth Trajectory and Initiatives
Historical Growth: Consult financial data or company press releases for information regarding past growth trends.
Future Projections: Future growth projections should be sourced from analyst reports and financial forecasts.
Recent Initiatives: Consult press releases for recent product launches and marketing plans.
Summary
LeMaitre Vascular is a relatively small but specialized company in the vascular surgery device market. It benefits from a strong brand and focused product line, but faces challenges from larger, more diversified competitors. Strategic acquisitions and expansion into new markets could drive future growth, but regulatory and economic factors pose ongoing risks.
Similar Companies
ABT
Abbott Laboratories
ABT
Abbott Laboratories
BSX
Boston Scientific Corp
BSX
Boston Scientific Corp
MDT
Medtronic PLC
MDT
Medtronic PLC
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is approximate and based on available information. Please consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About LeMaitre Vascular Inc
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 2006-10-19 | Chairman & CEO Mr. George W. LeMaitre | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 651 | Website https://www.lemaitre.com |
Full time employees 651 | Website https://www.lemaitre.com | ||
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It also provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular and porcine patches; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.